Recent studies are, therefore, trying to combine chemotherapies and immunotherapy in order to increase sensitivity to immunotherapy by modulating the tumor microenvironment for patients with EGFR-mutant NSCLC [89]. This evidence concerns the gene EGFR and neoplasm.